J. P. Moreau
4 Papers
186 Citations
J. P. Moreau is an academic researcher. The author has contributed to research in topics: Somatostatin receptor 2 & Somatostatin. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Alexandru Saveanu,Ginette Gunz,Henry Dufour,P. Caron,Frédéric Fina,L'Houcine Ouafik,Michael D. Culler,J. P. Moreau,Alain Enjalbert,P. Jaquet +9 more
TL;DR: Data indicate that due to heterogeneous expression of SSTR2 and SSTR5 receptor subtypes, in GH-secreting tumors, a bispecific analog that can activate both receptors could achieve better control of GH hypersecretion in a larger number of acromegalic patients.
Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
P. Jaquet,Alexandru Saveanu,Ginette Gunz,Frédéric Fina,Alfredo J. Zamora,Michel Grino,Michael D. Culler,J. P. Moreau,Alain Enjalbert,L'Houcine Ouafik +9 more
TL;DR: The quantitative expression of messenger ribonucleic acid for the 5 SSTR subtypes and the inhibitory effects of SRIF14; SRIF28; octreotide; the SSTR2-preferential analog, BIM-23197; and the S STR5-preferring analogs on GH and PRL secretion were analyzed, showing a highly variable ratio of the Sstr2 and SSTR5 transcripts, according to tumors.
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
P. Jaquet,Ginette Gunz,Alexandru Saveanu,H. Dufour,John E. Taylor,J Z Dong,Sun H. Kim,J. P. Moreau,Alain Enjalbert,Michael D. Culler +9 more
TL;DR: Novel dopamine-somatostatin chimeric molecules with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significatly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive toOctreotide therapy.
Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
P. Jaquet,L'Houcine Ouafik,Alexandru Saveanu,Ginette Gunz,Frédéric Fina,H. Dufour,Michael D. Culler,J. P. Moreau,Alain Enjalbert +8 more
TL;DR: Prolactinomas have a specific pattern of SSTR subtype mRNA expression (SSTR5 and SSTR1) that is correlated to PRL regulation, and inhibitory effects are superimposable, at a higher concentration, to those of the dopamine agonists, but are not additive.